Procter & Gamble Health Limited (NSE:PGHL)
India · Delayed Price · Currency is INR 4,887.50
+13.30 (0.27%)
At close: Mar 6, 2026
Procter & Gamble Health Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Operating Revenue | 13,485 | 12,181 | 11,513 | 12,296 | 11,144 | 10,087 |
Revenue | 13,485 | 12,181 | 11,513 | 12,296 | 11,144 | 10,087 |
Revenue Growth (YoY) | 16.30% | 5.80% | -6.37% | 10.34% | 10.48% | 13.52% |
Cost of Revenue | 3,782 | 3,490 | 3,425 | 3,834 | 3,531 | 3,245 |
Gross Profit | 9,703 | 8,691 | 8,087 | 8,463 | 7,614 | 6,842 |
Selling, General & Admin | 2,631 | 2,333 | 2,682 | 2,811 | 2,776 | 2,421 |
Other Operating Expenses | 3,049 | 2,689 | 2,340 | 2,412 | 2,141 | 1,943 |
Operating Expenses | 5,908 | 5,260 | 5,296 | 5,504 | 5,188 | 4,669 |
Operating Income | 3,795 | 3,431 | 2,791 | 2,959 | 2,426 | 2,173 |
Interest Expense | -4.7 | -6.3 | -7.2 | -7.7 | -4.2 | -8 |
Interest & Investment Income | 70.4 | 70.4 | 117.3 | 143.3 | 110.7 | 150.6 |
Currency Exchange Gain (Loss) | -1.6 | -1.6 | 2.7 | 3.4 | -6.9 | -8.9 |
Other Non Operating Income (Expenses) | 94.1 | 54.4 | 36.3 | 30.1 | 21.2 | 30.4 |
EBT Excluding Unusual Items | 3,953 | 3,548 | 2,940 | 3,128 | 2,546 | 2,337 |
Merger & Restructuring Charges | - | - | -201.9 | - | - | - |
Gain (Loss) on Sale of Assets | -1.3 | -1.3 | -5.1 | 7.1 | -5.4 | -4.2 |
Asset Writedown | - | - | - | 7.3 | -7.3 | - |
Other Unusual Items | - | -201.9 | - | - | - | - |
Pretax Income | 3,952 | 3,345 | 2,733 | 3,142 | 2,534 | 2,333 |
Income Tax Expense | 1,017 | 832.6 | 723.4 | 847.3 | 608.5 | 564.8 |
Earnings From Continuing Operations | 2,935 | 2,512 | 2,010 | 2,295 | 1,925 | 1,768 |
Net Income | 2,935 | 2,512 | 2,010 | 2,295 | 1,925 | 1,768 |
Net Income to Common | 2,935 | 2,512 | 2,010 | 2,295 | 1,925 | 1,768 |
Net Income Growth | 24.06% | 24.98% | -12.42% | 19.19% | 8.89% | 6.56% |
Shares Outstanding (Basic) | 17 | 17 | 17 | 17 | 17 | 17 |
Shares Outstanding (Diluted) | 17 | 17 | 17 | 17 | 17 | 17 |
Shares Change (YoY) | -0.00% | -0.00% | - | - | - | -0.08% |
EPS (Basic) | 176.81 | 151.33 | 121.08 | 138.24 | 115.98 | 106.51 |
EPS (Diluted) | 176.59 | 151.11 | 121.00 | 138.00 | 115.98 | 106.51 |
EPS Growth | 23.98% | 24.89% | -12.32% | 18.99% | 8.89% | 6.72% |
Free Cash Flow | - | 2,135 | 2,066 | 1,935 | 1,316 | 1,947 |
Free Cash Flow Per Share | - | 128.63 | 124.44 | 116.58 | 79.28 | 117.28 |
Dividend Per Share | - | 166.667 | 110.000 | 95.000 | 52.500 | 40.000 |
Dividend Growth | - | 51.52% | 15.79% | 80.95% | 31.25% | 42.86% |
Gross Margin | 71.95% | 71.35% | 70.25% | 68.82% | 68.32% | 67.83% |
Operating Margin | 28.14% | 28.17% | 24.24% | 24.06% | 21.77% | 21.54% |
Profit Margin | 21.76% | 20.62% | 17.46% | 18.66% | 17.28% | 17.53% |
Free Cash Flow Margin | - | 17.53% | 17.94% | 15.74% | 11.81% | 19.30% |
EBITDA | 3,943 | 3,621 | 3,034 | 3,188 | 2,648 | 2,424 |
EBITDA Margin | 29.24% | 29.73% | 26.36% | 25.92% | 23.76% | 24.03% |
D&A For EBITDA | 147.93 | 190.13 | 243 | 229 | 222.1 | 251.1 |
EBIT | 3,795 | 3,431 | 2,791 | 2,959 | 2,426 | 2,173 |
EBIT Margin | 28.14% | 28.17% | 24.24% | 24.06% | 21.77% | 21.54% |
Effective Tax Rate | 25.73% | 24.89% | 26.47% | 26.97% | 24.02% | 24.21% |
Revenue as Reported | 13,650 | 12,305 | 11,669 | 2,480 | 11,276 | 10,268 |
Advertising Expenses | - | - | 526.5 | 744.9 | 1,095 | 874.1 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.